



January 30, 2024

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIP CODE: 543748

To,
Listing/ Compliance Department
**National Stock Exchange of
India Limited**
“Exchange Plaza”, Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
SYMBOL: AARTIPHARM

Dear Sir/Madam,

Sub: Intimation of Board Meeting
**Ref: Regulation 29 of SEBI (Listing Obligations
and Disclosure Requirements) Regulations, 2015**

This is to inform that the meeting of the Board of Directors of Aarti Pharmalabs Limited ('the Company') is scheduled to be held on **Wednesday, February 7, 2024**, to inter-alia;

1. Consider, approve and take on record the Audited Financial Results for the quarter and nine months ended December 31, 2023;
2. Consider and declare Interim Dividend, if any, for the FY 2023-24;
3. Consider and approve any other business matter, if required, with the permission of Chair.

In pursuance to our intimation dated December 28, 2023, the trading window of the Company shall remain closed until February 09, 2024 for the aforesaid purpose.

Please take the same on your records.

Thanking you,

Yours faithfully,

For AARTI PHARMALABS LIMITED

NIKHIL NATU
COMPANY SECRETARY
ICSI M. NO. A27738

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655